Public disclosure of inside information according to article 17 MAR

Medigene AG: Medigene AG secures financing option through equity commitment of up to EUR 15 million

Planegg/Martinsried (pta035/08.10.2024/23:10 UTC+2)

Medigene AG (Medigene, FSE: MDG1, Prime Standard, ISIN DE000A40ESG2), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided immunotherapies for the treatment of cancer, today announces that it has entered into a Standby Equity Purchase Agreement (SEPA) with a fund managed by Yorkville Advisors Global, LP ("Yorkville").

The SEPA allows the Company to issue new Medigene shares from authorized capital under exclusion of the shareholders' subscription rights to Yorkville in several tranches for a total amount of up to EUR 15 million. Medigene may exercise this right at its own discretion and Yorkville is obliged to subscribe and purchase the requested number of shares subject to the terms and conditions of the SEPA. The number of shares that can be issued in a single tranche may not exceed the lower of (a) 400,000 shares and (b) 100% of the average of the daily trading volume during the five trading days immediately preceding the Company's request.

The subscription price to be paid by Yorkville for each share issued under the SEPA is equal to 95% of the average of the volume-weighted average price of the Medigene share for each of the five trading days following the advance request by Medigene.

This agreement has a term of 36 months from the date of signing. Yorkville has also entered into a share lending agreement with DJSMontana Holding GmbH, the holding company of Prof. Dr. Dolores Schendel, the Company's Chief Scientific Officer, pursuant to which DJSMontana Holding GmbH shall lend 400,000 Medigene shares to Yorkville in order to support the transaction.

Medigene intends to use the capital raised for the further development of the Company's programs.

(end)

---

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A40ESG2 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate

[ source: https://www.pressetext.com/news/1728421800784 ]

(c) pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext. Archive: https://www.pressetext.com/channel/Adhoc The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.